• QUID-NASH

    Home

  • Operandi

    https://fhu-mosaic.com/operandi/

    Internal radiotherapies (radioembolization and vectorized internal radiotherapy) which treat certain digestive cancers (HCC and NET) are insufficiently accompanied by methods for patient stratification and early identification of responders. OPERANDI therefore offers an approach: “better select, better treat, better monitor” which aims to better select candidates for these treatments, improve patient survival, reduce costs for the health system, and develop new industrial products. /p>

    OPERANDI intends to develop AI algorithms based on predictive and prognostic multi-scale imaging, develop a holistic approach to therapy guided simultaneously by PET-MRI, decode the phenomena radio-resistance and tumor response to treatments, and evaluate new combinations of drugs and radiopharmaceuticals.

    This consortium brings together leading clinical and research teams: AP-HP (coordinating establishment), Nantes University Hospital, Inserm , University of Paris, GIP ARRONAX, AFEF, CIRSE; as well as industrial partners at the forefront of translational technologies applied to patients: Siemens Healthineers, LXRepair, NH TherAguix.

  • Liver-Track

    https://recherche-hopitauxnord-u-pariscite.aphp.fr/le-projet-de-recherche- hospitalo-universitaire-rhu-liver-track-winner-of-the-call-for-project-from-the-national-research-Agence/

    The RHU LIVER-TRACK research program will make it possible to use the full potential of extracellular vesicles, small fragments of cells that circulate in the blood, to predict disease complications of the liver” with the slogan “Better prediction is better care”, explains Professor Pierre-Emmanuel Rautou, coordinator of the RHU LIVER-TRACK at Beaujon hospital.